ZA201006263B - Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts - Google Patents

Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Info

Publication number
ZA201006263B
ZA201006263B ZA2010/06263A ZA201006263A ZA201006263B ZA 201006263 B ZA201006263 B ZA 201006263B ZA 2010/06263 A ZA2010/06263 A ZA 2010/06263A ZA 201006263 A ZA201006263 A ZA 201006263A ZA 201006263 B ZA201006263 B ZA 201006263B
Authority
ZA
South Africa
Prior art keywords
benzimidazol
methylpiperazin
quinolin
fluoro
amino
Prior art date
Application number
ZA2010/06263A
Other languages
English (en)
Inventor
Andreas Schreiner
Johanne Polasek
Philippe Piechon
Walter Hammerschmidt
Danielle Giron
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201006263(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201006263B publication Critical patent/ZA201006263B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2010/06263A 2008-03-19 2010-09-01 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts ZA201006263B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19
PCT/EP2009/053222 WO2009115562A2 (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Publications (1)

Publication Number Publication Date
ZA201006263B true ZA201006263B (en) 2011-05-25

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/06263A ZA201006263B (en) 2008-03-19 2010-09-01 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Country Status (24)

Country Link
US (1) US8563556B2 (enExample)
EP (1) EP2257544B1 (enExample)
JP (1) JP2011515370A (enExample)
KR (1) KR20100137517A (enExample)
CN (1) CN101970425B (enExample)
AR (1) AR070924A1 (enExample)
AU (1) AU2009227003B2 (enExample)
BR (1) BRPI0909762A2 (enExample)
CA (1) CA2718076A1 (enExample)
CL (1) CL2009000651A1 (enExample)
CO (1) CO6321253A2 (enExample)
EC (1) ECSP10010555A (enExample)
IL (1) IL208020A0 (enExample)
MA (1) MA32230B1 (enExample)
MX (1) MX2010010152A (enExample)
MY (1) MY150554A (enExample)
NZ (2) NZ600887A (enExample)
PE (1) PE20091628A1 (enExample)
PH (2) PH12012502568A1 (enExample)
RU (1) RU2497820C2 (enExample)
SG (1) SG188919A1 (enExample)
TW (1) TWI426072B (enExample)
WO (1) WO2009115562A2 (enExample)
ZA (1) ZA201006263B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
SG184311A1 (en) 2010-04-16 2012-11-29 Novartis Ag Combination of organic compounds
CA2793779A1 (en) 2010-04-16 2011-10-20 Novartis Ag Organic compound for use in the treatment of liver cancer
AR081776A1 (es) * 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
CN103429759A (zh) 2011-03-17 2013-12-04 诺华股份有限公司 Fgfr及其配体作为hr阳性对象中乳腺癌的生物标记
SG194445A1 (en) 2011-05-19 2013-12-30 Novartis Ag Method for treating adenoid cystic carcinoma
IN2014DN02060A (enExample) 2011-09-15 2015-05-15 Novartis Ag
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
AU2013289175A1 (en) 2012-07-11 2015-01-22 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
AU2003290699B2 (en) 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
MXPA06004194A (es) * 2003-11-07 2006-06-28 Chiron Corp Inhibicion de fgfr3 y tratamiento de mieloma multiple.
RU2377988C2 (ru) * 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
WO2006081445A2 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Treatment of metastasized tumors
KR101368519B1 (ko) * 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
PL1957074T3 (pl) * 2005-11-29 2014-08-29 Novartis Ag Preparaty chinolinonów
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona

Also Published As

Publication number Publication date
PH12012502569A1 (en) 2015-09-21
WO2009115562A2 (en) 2009-09-24
ECSP10010555A (es) 2010-11-30
PE20091628A1 (es) 2009-11-19
HK1147492A1 (en) 2011-08-12
BRPI0909762A2 (pt) 2018-04-03
CL2009000651A1 (es) 2010-07-19
EP2257544B1 (en) 2014-12-03
SG188919A1 (en) 2013-04-30
US8563556B2 (en) 2013-10-22
PH12012502568A1 (en) 2014-10-27
NZ587829A (en) 2012-08-31
IL208020A0 (en) 2010-12-30
KR20100137517A (ko) 2010-12-30
CA2718076A1 (en) 2009-09-24
NZ600887A (en) 2013-10-25
AU2009227003B2 (en) 2013-03-14
AU2009227003A1 (en) 2009-09-24
MX2010010152A (es) 2010-10-25
AR070924A1 (es) 2010-05-12
RU2497820C2 (ru) 2013-11-10
CN101970425A (zh) 2011-02-09
RU2010142396A (ru) 2012-04-27
MY150554A (en) 2014-01-30
US20110021536A1 (en) 2011-01-27
CN101970425B (zh) 2014-04-16
JP2011515370A (ja) 2011-05-19
TW201000463A (en) 2010-01-01
TWI426072B (zh) 2014-02-11
EP2257544A2 (en) 2010-12-08
WO2009115562A3 (en) 2009-11-26
CO6321253A2 (es) 2011-09-20
MA32230B1 (fr) 2011-04-01

Similar Documents

Publication Publication Date Title
IL208020A0 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
IL223350A0 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
EP2136824A4 (en) USE OF SELECTED MILKY ACID BACTERIA TO REDUCE ATHEROSCLEROSIS
IL215472A0 (en) Salt of abt-263 and solid-state forms thereof
PT2334295T (pt) Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
IL194779A0 (en) Use of selected lactic acid bacteria for reducing infantile colic
ZA201004670B (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
EP2094665A4 (en) PREPARATION OF MONTELUKAST AND ITS SALTS
EP1988155A4 (en) LACTIC ACID BACTERIUM CAPABLE OF PRODUCING AMINO-ACUTE ACID
EP2619194A4 (en) CATECHIN FATTY ACID DERIVATIVES AND METHODS OF USE
EP2265586A4 (en) PREPARATION OF MONTELUKAST AND ITS SALTS
PL2001862T3 (pl) Jabłczany oraz odmiany polimorficzne kwasu (3S,5S)-7-[3-amino-5-metylo-piperydynylo]-1-cyklopropylo-1,4-dihydro-8-metoksy-4-okso-3-chinolinokarboksylowego
IL219934A0 (en) Quinazolin-4(3a)-one derivatives and methods of use thereof
IT1395963B1 (it) Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
ZA201105542B (en) Cefdinir acid double salt and its preparation
TH0901001214A (th) รูปแบบที่เป็นผลึก และสองรูปแบบที่เป็นซอลเวทของเกลือ 4-อะมิโน-5-ฟลูออโร-3-[5-(4-เมทธิลพิเพอราซิน-1-อิล)-1h-เบนซิมิดาซอล-2-อิล]ควิโนลิน-2(1h)-โอน แลคติก แอซิด
IL215512A0 (en) Substituted 1-alkylcinnolin-4(1h)-one derivatives, preparation thereof and therapeutic application of same
IL192554A0 (en) Controlled release formulation of divalproic acid and its derivatives
TN2010000418A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
HK1109772A (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
IL216782A0 (en) Solid states forms of varenicline salts and processes for preparation therrof
PH12012500744A1 (en) Conditioning composition comprising amidoamine and lactic acid
PL2128152T3 (pl) Proces oczyszczania cyklicznych diestrów kwasu L-lub D-mlekowego
HK40104059A (zh) 来那替尼马来酸盐及晶形